Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization

Eisai Co., Ltd. announced that it has received approval for a partial label change for the vascular embolization device DC Bead (specially controlled medical device) in Japan. The product is to be used for transcatheter arterial embolization in patients with hypervascular tumors (excluding uterine fibroids).

In real-world clinical settings, it was found that DC Bead was not being used in the treatment of uterine fibroids and arteriovenous malformations. Following confirmation at related academic associations and subsequent consultation with the regulatory authority, an application for a partial label change for the relevant indication was submitted, upon which this approval is based.

With the partial label change for DC Bead, Eisai is striving to ensure that accurate information is provided to healthcare professionals.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Harvard’s Wyss Institute joins forces with Cytosurge to improve CRISPR-based multiplexed gene editing